2021: Phase 2 trial results in T1DM presented at ADA annual meeting

Results from the Phase 2 clinical trial of Volagidemab (REMD-477) in Type 1 diabetes patients were presented during oral session titled "Novel Therapeutic Agents and Approaches" at the 81st American Diabetes Association meeting

2021: Human proof of concept for REMD-477 in treating PI3K inhibitor-induced hyperglycemia in breast cancer and lymphoma patients published

A paper was published in the journal Leukemia and Lymphoma demonstrating the clinical proof of concept for the treatment of PI3K inhibitor-induced hyperglycemia with Volagidemab (REMD-477) in cancer patients

2020: Phase 2 trial of REMD-477 in T1DM completed

The Phase 2 clinical trial for Volagidemab (REMD-477) in Type 1 diabetes patients was completed in 2020

2019: Preclinical proof of concept studies for REMD-477 to treat heart failure published

Multiple articles were published demonstrating the protective effects of REMD-477 in preclinical heart failure models

2019: Antigen Targeted Attenuated Cytokine (ATAC) platform established

The ATAC platform was established in 2019 to develop novel antibody-cytokine mutein fusion proteins for cancer immunotherapy

2019: Research collaboration established with Genscript ProBio

REMD Bio and Genscript ProBio established a research collaboration to develop novel bispecific antibodies

2019: SynermAb bispecific antibody platform established

The SynermAb Bispecific Antibody platform was established in 2019

2018: Phase 2 trial of REMD-477 in T2DM completed

The Phase 2 clinical study of Volagidemab (REMD-477) in Type 2 diabetes was completed in 2018

2018: Strategic partnership with Buchang Bio established for development of cancer immunotherapies

A strategic partnership was established with Buchang Bio for the development of cancer immunotherapies

2017: ADA Presidential Oral Presentation of Phase 1b trial data of REMD-477 (Volagidemab) in T1DM

Phase 1b trial data in Type 1 diabetes was selected as Presidential Oral Presentation at the 77th American Diabetes Association (ADA) Annual Meeting

2016: First patient dosed in Phase 1b trial of REMD-477 in T1DM

The first patient in the Phase 1b trial for REMD-477 in Type 1 diabetes was dosed

2016: G Protein Coupled Receptor (GPCR) Antibody Discovery platform established

The GPCR Antibody platform was established in 2016 to develop novel therapeutic antibodies against GPCR targets

2015: Preclinical proof of concept study for REMD-477 in T1DM published

Preclinical proof of concept study of REMD-477 in Type 1 diabetes was published in the journal PNAS

2015: First patient dosed in Phase 2 trial of REMD-477 for T2DM

The first patient was dosed in the Phase 2 clinical study of REMD-477 in patients with Type 2 diabetes

2015: IND approved by FDA for REMD-477

The FDA approved the IND application filed for REMD-477

2014: Founding of Cosci-REMD Bio

China subsidiary Cosci-REMD Biotherapeutics was founded in Beijing

2013: FDA lifts clinical hold on REMD-477

Clinical hold on REMD-477 program was lifted by the FDA

2013: Licensed AMG477 from Amgen

Licensed glucagon receptor antagonist antibody AMG477 from Amgen, which became REMD-477 and now Volagidemab

2012: REMD Biotherapeutics founded in Camarillo, CA, USA

REMD Biotherapeutics, Inc. was founded